Shire PLC Company Profile (NASDAQ:SHPG)


Shire PLC logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SHPG
  • CUSIP: N/A
  • Web:
Average Prices:
  • 52 Week Range: $139.36 - $192.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 9.42
  • P/E Growth: 0.00
  • Annual Dividend: $0.92
  • Dividend Yield: 0.6%
  • Net Margins: 4.70%
  • Return on Equity: 14.10%
  • Return on Assets: 6.25%
  • Debt-to-Equity Ratio: 0.59%
  • Current Ratio: 0.96%
  • Quick Ratio: 0.52%
  • Beta: 1.63

Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)

What is Shire PLC's stock symbol?

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC announced a semiannual dividend on Friday, August 11th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.1527 per share on Friday, October 20th. This represents a dividend yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. View Shire PLC's Dividend History.

How were Shire PLC's earnings last quarter?

Shire PLC (NASDAQ:SHPG) posted its earnings results on Friday, October, 27th. The company reported $3.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $3.66 by $0.29. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. View Shire PLC's Earnings History.

When will Shire PLC make its next earnings announcement?

Shire PLC is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Shire PLC.

What guidance has Shire PLC issued on next quarter's earnings?

Shire PLC issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus estimate of $14.85. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $15.04 billion.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

20 brokers have issued twelve-month price objectives for Shire PLC's stock. Their predictions range from $159.00 to $325.00. On average, they anticipate Shire PLC's stock price to reach $220.91 in the next twelve months. View Analyst Ratings for Shire PLC.

What are analysts saying about Shire PLC stock?

Here are some recent quotes from research analysts about Shire PLC stock:

  • 1. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
  • 2. According to Zacks Investment Research, "Shire reported encouraging Q2 results, beating estimates for both sales and earnings.The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 23% of the total market by the end of Jun 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry." (8/8/2017)
  • 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Are investors shorting Shire PLC?

Shire PLC saw a increase in short interest in September. As of September 15th, there was short interest totalling 2,423,090 shares, an increase of 57.8% from the August 31st total of 1,535,236 shares. Based on an average trading volume of 1,397,911 shares, the short-interest ratio is presently 1.7 days.

Who are some of Shire PLC's key competitors?

Who are Shire PLC's key executives?

Shire PLC's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director
  • Jeffrey Poulton, Chief Financial Officer, Executive Director
  • Joanne Cordeiro, Chief Human Resource Officer
  • William Mordan, General Counsel, Company Secretary
  • Perry Sternberg, Head - U.S. Commercial
  • Kim Stratton, Head - International Commercial
  • Philip J. Vickers, Head - Research and Development
  • Matthew Walker, Head - Technical Operations
  • Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
  • Olivier Bohuon, Non-Executive Director

How do I buy Shire PLC stock?

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire PLC's stock price today?

One share of Shire PLC stock can currently be purchased for approximately $152.05.

MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  817 (Vote Outperform)
Underperform Votes:  348 (Vote Underperform)
Total Votes:  1,165
MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $220.91 (45.29% upside)
Consensus Price Target History for Shire PLC (NASDAQ:SHPG)
Price Target History for Shire PLC (NASDAQ:SHPG)
Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/11/2017Royal Bank Of CanadaReiterated RatingOutperform -> Outperform$213.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
9/14/2017Cantor FitzgeraldReiterated RatingBuy$222.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017Barclays PLCDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingHold$216.00 -> $206.00LowView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$159.00MediumView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00LowView Rating Details
7/6/2017HSBC Holdings plcUpgradeReduce -> HoldMediumView Rating Details
6/1/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
5/31/2017Cowen and CompanyReiterated RatingOutperform$325.00LowView Rating Details
4/17/2017Goldman Sachs Group, Inc. (The)Boost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/3/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
3/30/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna Bancshares IncLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
1/18/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
10/21/2015William BlairReiterated RatingOutperform$276.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Shire PLC (NASDAQ:SHPG)
Earnings by Quarter for Shire PLC (NASDAQ:SHPG)
Earnings History by Quarter for Shire PLC (NASDAQ SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2017$3.66$3.37ViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.75 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.74
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.22$3.36$3.31
Q2 20174$3.53$3.69$3.61
Q3 20174$3.59$3.89$3.73
Q4 20174$3.75$4.26$4.09
(Data provided by Zacks Investment Research)


Current Dividend Information for Shire PLC (NASDAQ:SHPG)
Next Dividend:10/20/2017
Annual Dividend:$0.92
Dividend Yield:0.61%
Payout Ratio:41.07% (Trailing 12 Months of Earnings)
6.17% (Based on This Year's Estimates)
5.70% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire PLC (NASDAQ:SHPG)

Dividend History by Quarter for Shire PLC (NASDAQ SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by


Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
DateHeadline logoZacks: Brokerages Anticipate Shire PLC (SHPG) Will Announce Quarterly Sales of $3.77 Billion - October 17 at 9:30 AM logo Brokerages Anticipate Shire PLC (SHPG) to Announce $3.66 EPS - October 15 at 4:26 AM logoShire : ONCASPAR Gets Positive CHMP Opinion In Europe For Patients With ALL - October 14 at 7:50 AM logoEuropean advisory group backs Shire's lyophilized Oncaspar for ALL - October 14 at 7:50 AM logoShire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients ... - GlobeNewswire (press release) - October 13 at 2:14 AM logoShire Q3/2017: Earnings Preview - Seeking Alpha - October 12 at 4:06 PM logoShire PLC (SHPG) Receives "Outperform" Rating from Royal Bank Of Canada - October 11 at 8:02 AM logoETFs with exposure to Shire Plc : October 10, 2017 - October 11 at 7:43 AM logoShire Plc :SHPG-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 - October 10 at 6:50 AM logoShire PLC (SHPG) Rating Reiterated by Stifel Nicolaus - October 8 at 4:14 PM logoShire PLC (SHPG) Given Average Recommendation of "Buy" by Brokerages - October 7 at 2:38 PM logoShire PLC (SHPG) Sees Significant Growth in Short Interest - September 29 at 1:56 AM logoNektar's Lead Drugs Drive Growth, Partner Reliance a Woe - September 27 at 8:42 AM logoShire PLC (SHPG) Expected to Post Earnings of $3.66 Per Share - September 26 at 12:30 PM logoSupernus Drops SPN-810's Lower Dose Test in Phase III Trials - Nasdaq - September 20 at 9:00 AM logoShire's Intuniv successful in late-stage study in adult ADHD - Seeking Alpha - September 20 at 9:00 AM logoShire PLC (SHPG) Sees Significant Increase in Short Interest - September 16 at 1:20 AM logoShire PLC (SHPG) Receives Buy Rating from Cantor Fitzgerald - September 15 at 3:36 PM logoShire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress - September 15 at 8:51 AM logoShire to present research on recently approved ADHD med Mydayis at upcoming Psych Congress; shares up 2% premarket - September 15 at 8:51 AM logoWhat’s Cooperman’s View on Shire? - September 15 at 8:51 AM logoShire (SHPG) Presents at Morgan Stanley Global Healthcare Conference (Transcript) - Seeking Alpha - September 14 at 10:05 AM logoShire (SHPG) Says Phase 3 SAHARA Study Met Primary Endpoint (Earlier) - September 13 at 9:08 AM logoLeon Cooperman: Stock Market Valuations Are 'Full But Fair' - September 13 at 9:08 AM logoSmart Medical Device Could Save Millions of Lives - September 13 at 9:08 AM logoShire PLC (SHPG) Receives Consensus Recommendation of "Buy" from Analysts - September 12 at 4:48 PM logoShire (SHPG) Says Phase 3 SAHARA Study Met Primary Endpoint (Earlier) - - September 12 at 9:46 AM logoLate-stage study assessing subcutaneous formulation of Shire's ... - Seeking Alpha - September 12 at 9:46 AM logoInteresting SHPG Put And Call Options For January 2020 - Nasdaq - September 12 at 9:46 AM logoShire Plc Announces Fast Track Designation For SHP607 - Quick Facts - Nasdaq - September 12 at 9:45 AM logoDaily Technical Summary Reports on Healthcare Stocks -- Shire, Aerie Pharma, Heron Therapeutics, and United Therapeutics - September 11 at 6:49 AM logo$3.77 Billion in Sales Expected for Shire PLC (SHPG) This Quarter - September 9 at 5:42 AM logoHere's Why Shire PLC Stock Fell 10% in August - September 8 at 8:21 AM logoHere's Why Shire PLC Stock Fell 10% in August - September 7 at 2:01 PM logoCorporate News Blog - Sanofi Completes Acquisition of Vaccines Biotechnology Company, Protein Sciences - August 30 at 9:09 AM logoOpko Health (OPK) & Shire PLC (SHPG) Critical Survey - August 29 at 12:22 AM logoAnalysts Predict 16% Upside For PPH - Nasdaq - August 25 at 9:09 PM logoRoche Is Almost At The Finish Line - August 25 at 11:36 AM logoShire plc (SHPG) CFO Jeff Poulton to Leave at End of Year to Join Start-Up Indigo Ag - - August 23 at 11:35 AM logoShire PLC (SHPG) Given "Buy" Rating at Cantor Fitzgerald - August 21 at 3:28 PM logoShire plc Director and Senior Management Changes - August 21 at 10:21 AM logoShire PLC (SHPG) Given Average Rating of "Buy" by Analysts - August 18 at 5:26 PM logoShire Files Marketing Application for Lifitegrast in Europe - Nasdaq ... - Nasdaq - August 17 at 4:37 PM logoShire PLC (SHPG) Research Coverage Started at Evercore ISI - August 16 at 6:26 PM logoShire submits marketing application in Europe for lifitegrast for dry eye disease - August 16 at 7:29 AM logoShire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe - August 16 at 7:29 AM logoShire PLC (SHPG) Earns "Buy" Rating from Cantor Fitzgerald - August 15 at 11:16 AM logoShire applies for European approval of potential blockbuster eye drop - August 15 at 6:56 AM logoShire PLC (NASDAQ:SHPG) Plans $0.15 Semiannual Dividend - August 11 at 6:06 PM logoShire PLC (NASDAQ:SHPG) Lowered to Equal Weight at Barclays PLC - August 11 at 4:04 PM



Shire PLC (SHPG) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.